Aldeyra Therapeutics, Inc. - ALDX STOCK NEWS

Aldeyra Therapeutics (Nasdaq: ALDX) reported its financial results for Q2 2021, highlighting a net loss of $14.9 million compared to $7.5 million in Q2 2020. Cash reserves stand at $249.7 million, sufficient to fund operations through 2023. The company anticipates results from its Phase 3 TRANQUILITY trials for reproxalap in dry eye disease by Q4 2021, alongside outcomes from Phase 2 trials of ADX-629 for immune-mediated diseases. Additionally, the FDA granted orphan drug designation for ADX-2191 in two retinal diseases, enhancing development incentives.

Aldeyra Therapeutics (Nasdaq: ALDX) has received orphan drug designation from the FDA for ADX-2191, indicated for treating retinitis pigmentosa (RP), a rare genetic eye disease affecting up to 110,000 individuals in the U.S. This designation signifies the unmet medical need in ophthalmology. ADX-2191 also holds orphan drug designation for primary vitreoretinal lymphoma and fast track designation for preventing proliferative vitreoretinopathy. These regulatory recognitions offer financial incentives under the FDA's orphan drug program, including potential marketing exclusivity.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that President and CEO Todd C. Brady, M.D., Ph.D., will participate in analyst-led fireside chats at two upcoming virtual conferences.

• BTIG Virtual Biotechnology Conference
  Date: August 9, 2021, Time: 9:30 a.m. ET
• H.C. Wainwright Ophthalmology Virtual Conference
  Date: August 17, 2021, Time: Available On-Demand from 7:00 a.m. ET

Access details are available on Aldeyra’s Investor & Media page, with archives for 90 days post-event.

Aldeyra Therapeutics (Nasdaq: ALDX) announced that the FDA has granted orphan drug designation for ADX-2191, a methotrexate treatment for primary vitreoretinal lymphoma (PVRL), a rare cancer affecting about 2,800 individuals in the U.S. annually. This designation supports clinical development and commercialization, providing tax incentives and potential seven-year marketing exclusivity. ADX-2191 is also in Phase 3 trials for preventing proliferative vitreoretinopathy, a major complication of retinal surgery. Orphan drug status can enhance funding and development prospects for Aldeyra's pipeline.

Aldeyra Therapeutics (Nasdaq: ALDX) has been included in both the Russell 3000 and Russell 2000 indexes, effective June 28, 2021. This addition reflects the company's growing market capitalization and investor interest, driven by advancements in their clinical pipeline, including reproxalap for dry eye disease and allergic conjunctivitis, and ADX-629 for systemic diseases. The Russell indexes are vital benchmarks for investment strategies, with about $10.6 trillion in assets tied to them.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced that its President and CEO, Todd C. Brady, M.D., Ph.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 p.m. ET. A live webcast of the event will be available on the company's investor relations page and archived for 90 days afterward. Aldeyra focuses on developing treatments for immune-mediated diseases, with key products in clinical trials, including reproxalap for dry eye disease and allergic conjunctivitis.

Aldeyra Therapeutics (Nasdaq: ALDX) reported Q1 2021 financial results, highlighting significant progress in clinical trials for its lead product, reproxalap. The Phase 3 INVIGORATE Trial showed statistically significant improvement in allergic conjunctivitis symptoms. Aldeyra anticipates meeting with the FDA regarding a potential New Drug Application. The company completed a public offering, raising $125 million, ensuring financing through 2023. Q1 net loss was $11.3 million, up from $9.9 million year-over-year, primarily due to R&D expenses.

Aldeyra Therapeutics (Nasdaq: ALDX) is set to host a conference call on May 6, 2021, at 8:00 a.m. ET to discuss its financial results for Q1 2021, ending March 31, 2021. The live call can be accessed via dial-in numbers for domestic (866-211-4098) and international (647-689-6613) callers. The company focuses on developing innovative therapies for immune-mediated diseases, with lead compounds reproxalap and ADX-629 currently in clinical trials.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has priced a public offering of 10,000,000 shares at $12.50 per share, aiming to raise $125 million. The proceeds will fund preparations for a potential New Drug Application for its lead compound, reproxalap, and other corporate purposes. An additional 1,500,000 shares may be purchased by underwriters within 30 days. The offering is set to close around May 3, 2021, pending customary conditions. Jefferies and SVB Leerink are joint book-running managers, with other firms as co-lead managers.